A high copy number of CCL3L1, the most potent human immunodeficiency virus (HIV)suppressive chemokine, associates with reduced HIV susceptibility. Whether CCL3L1 influences acquisition of multiple blood-borne infections (eg, hepatitis C virus [HCV], HIV, and hepatitis B virus [HBV] infections), which occur commonly among injection drug users (IDUs), is unknown.
Complex interactions between 3 parameters-environment, microbial agent, and host genotype-are thought to be a key determinant of the outcome of infectious challenge [1] . Conceptually, environmental factors may be parameters that are intrinsic to the host, such as coinfections. Abundant data support the relevance of investigating the factors that influence human immunodeficiency virus (HIV) pathogenesis in the context of microbial co-pathogens [2] [3] [4] [5] [6] [7] [8] , especially hepatitis C virus (HCV) and hepatitis B virus (HBV), which are like-1 (CCL3L1), CCL3, CCL4, CCL4L1, and CCL5 are the main ligands of CCR5, and they inhibit entry of HIV into CD4 + T cells in vitro [10, 11, [13] [14] [15] [16] . In addition, CCR5 ligands may affect HIV pathogenesis by influencing several facets of the immune response, including cell-mediated immunity [17] [18] [19] [20] [21] [22] . Notably, among the CCR5 chemokine ligands, CCL3L1 is the most potent and has maximal HIV-suppressive properties in vitro [14] [15] [16] . The region on chromosome 17q that encodes several CCR5 ligands is a hot spot for segmental duplications, such that individuals vary with respect to the number of CCL3L1-containing segmental duplications [16, [23] [24] [25] [26] [27] . Hence, individuals differ with regards to the copy number of genes that are found in this segmental duplication, including chemokine genes, such as CCL3L1 and CCL4L1 [16, [23] [24] [25] [26] [27] . Previous studies have found that persons of European origin possess 1-6 CCL3L1 gene-containing segmental duplications (henceforth designated as CCL3L1 copies) with an average of 2 copies [24] [25] [26] 28] . By contrast, those of African descent possess higher CCL3L1 copy numbers than do those of European descent [24, 26, [29] [30] [31] .
A low CCL3L1 copy number is associated with reduced chemokine levels and a higher proportion of CCR5-expressing CD4 + cells [24, 25] . Genetic association studies found that a low CCL3L1 copy number was associated with an increased risk of acquiring HIV infection in European-American, African-American, and Hispanic-American adults infected primarily through the mucosal route [24] ; hemophiliacs from Japan [32] ; and Argentinean [24] , South African [29, 30] and Ukrainian [28] children exposed perinatally to HIV.
Previous studies have found that a genetic factor may confer differential effects, depending on the route of infection. For example, Martin et al [33] showed that a DC-SIGN promoter polymorphism was associated with increased risk for parenteral, but not mucosal, acquisition of HIV infection. Although the results of the studies involving hemophiliacs are suggestive [32] , most of the prior studies that defined the association of a high CCL3L1 copy number with decreased HIV susceptibility were primarily conducted among subjects infected via the mucosal or perinatal route [24, [28] [29] [30] 32] . To determine whether there was a relationship between CCL3L1 copy number and risk of acquiring infection following parenteral exposure to HIV, we examined injection drug users (IDUs).
We investigated IDU's of European descent from Estonia, a geographic region in which the HIV epidemic is relatively new [34] . The outbreaks in Estonia were first detected among IDUs in 2000, and HIV infection is still concentrated among this population [34] . Furthermore, infection with HIV among these IDUs is accompanied by a very high frequency of viral coinfections with HCV and HBV [35] . This provided the unique opportunity to examine whether there was an independent association of CCL3L1 copy number with these 2 viral infections.
In addition to the copy number of CCL3L1, we determined the association of the 32-base pair deletion mutation in CCR5 (CCR5-D32) with HIV susceptibility, because previous studies have demonstrated that homozygyosity for this polymorphism is associated with resistance to HIV infection [10] [11] [12] ; the associations of CCR5-D32/D32 with HCV susceptibility vary between cohorts [36] [37] [38] [39] . The results of our study confirm and extend significantly the notion that CCL3L1 plays a critical role in HIV susceptibility and also underscore the importance of accounting for complex interactions among HCV, HIV, and CCL3L1 genotype when analyzing genotype-phenotype (HIV susceptibility) relationships.
METHODS

Subjects and sample collection.
The study subjects were recruited in 2006 and 2007 from the Estonian syringe exchange programs and 3 Estonian prisons; 374 ancestrally Caucasian IDUs were enrolled (301 male subjects, 55 female subjects, and 18 subjects whose sex was unknown; median age, 26 years; 95% of the subjects were antiretroviral therapy naive). Data on the duration of injection drug use (IDU) was available for 249 subjects. All study subjects reported use of injection drugs for a minimum of 1 year, with most subjects having longer periods of IDU. From each subject, 2 samples of 8 mL of venous blood were collected and transported immediately to the laboratory. The first blood sample was used for detection of HIV, HCV, and HBV serostatus, and the second sample was used later for genotyping analyses.
HIV, HCV, and HBV serostatus. HIV testing was performed in the Estonian Central HIV Reference Laboratory (Tallinn, Estonia) using a fourth-generation enzyme-linked immunoassay (Vironistica HIV Uniform II Ag/Ab; BioMérieux); all positive results were confirmed by an immunoblotting assay (INNO LIA HIV I/II Score Westernblot; Microgen Bioproducts). The presence of HCV antibodies was tested for with the ETI-AB-HCVK-3 anti-HCV test (DiaSorin). HBV seropositivity was assessed by ETI-MAK-4 HBsAg (DiaSorin) and ETI-AB-COREK Plus (anti-HBc core) (DiaSorin).
Genotyping of CCR5 and CCL3L1 variations. Genomic DNA was extracted from peripheral blood mononuclear cells (courtesy of Ismo Virtanen of the University of Helsinki, Helsinki, Finland) using the Qiagen QIAamp DNA minikit (Qiagen). CCR5-D32 mutation was assessed using polymerase chain reaction (PCR) restriction fragment length polymorphism, as described elsewhere [40] . CCL3L1 copy number was determined using quantitative real-time PCR with primers, probes, and experimental conditions exactly as described elsewhere [24] .
Statistical analyses. Differences in gene copy numbers and other covariates were assessed by the x 2 tests. Univariate and multivariate logistic regression models were used to determine the association of CCR5 or CCL3L1 genotype and other covariates with HIV or HCV status. Interactive multivariate logistic regression analyses were also conducted to assess the interactions between duration of IDU and CCL3L1 copy number. Stata, version 6.0 (Stata Corporation) was used for the statistical analyses. The study was approved by the Ethics Committee of Tallinn; all participants signed the informed consent.
RESULTS
HCV, HIV, and HBV serostatus.
Among the study subjects, 76%, 56%, and 15% were infected with HCV, HIV, and HBV, respectively ( Table 1 ). Approximately one-third (133 of 374) were HIV and HCV positive, 1% (4 of 374) were HIV and HBV positive, 12% (44 of 374) were HIV, HCV, and HBV positive, 7% (27 of 374) were HIV positive but HCV and HBV negative, and 27% (100 of 374) were HCV positive but HIV and HBV negative. Of the remaining 66 subjects, 53 were HIV, HCV, and HBV negative or had other combinations of viral infection. CCR5-D32 genotype and HIV infection. CCR5-D32 homozygotes were not detected among HIV-positive subjects, whereas 4 of 162 HIV-negative subjects had the CCR5-D32/ D32 genotype. The prevalence of CCR5-D32 heterozygotes among HIV-positive and HIV-negative subjects was similar (19% and 20%, respectively). The distribution of CCR5-D32 homozygosity or heterozygosity between HIV-negative, HCVpositive subjects and HIV-negative, HCV-negative subjects was similar (3 of 105 vs 1 of 56 for D32/D32 and 24 of 108 vs 9 of 57 for D32 heterozygosity).
Distribution of CCL3L1 copy numbers. The median CCL3L1 copy number in the entire study population was 2 (range, 0-6). The distribution of the CCL3L1 copy numbers between HIV-positive and HIV-negative subjects was significantly different ( ; ), such that HIV-negative 2 x p 4.99 P ! .05 subjects possessed higher gene copy numbers than did HIVpositive subjects ( Figure 1A) . By contrast, the distribution of CCL3L1 copy numbers among HCV-positive vs HCV-negative subjects was similar ( Figure 1B) .
Association of CCL3L1 copy number and HIV and HCV serostatus. We observed a clear shift in the frequency distributions of CCL3L1 copy number between 2 and 3 copies in HIV-positive vs HIV-negative subjects ( Figure 1A ). Compared with those subjects with р2 CCL3L1 copies, those with 3 copies had a nearly 50% lower risk of HIV seropositivity (odds ratio [OR], 0.50; 95% confidence interval [CI], 0.26-0.96; P p ). Similarly protective associations were observed for those .037 subjects with 4 copies (OR, 0.50; 95% CI, 0.19-1.29; ) P p .15 or 5-6 copies (OR, 0.39; 95% CI, 0.11-1.38;
), but these P p .14 associations did not achieve statistical significance at . P ! .05 On the basis of these results and the distribution pattern of CCL3L1 copy number among HIV-positive vs HIV-negative IDUs ( Figure 1A ), subjects were categorized into 2 groupsthose with a CCL3L1 copy number from 0 through 2 and those with 12 (high CCL3L1 copy number). In univariate analyses, predictably, co-infection with HCV (OR, 3.01; 95% CI, 1.83-4.96) and HBV (OR, 5.10; 95% CI, 2.42-10.75), and longer duration of IDU (OR, 1.08; 95% CI, 1.01-1.15) were each associated with a significantly increased likelihood of HIV seropositivity ( Table 2) . A copy number of CCL3L1 that was 12 was associated with a 50% decreased likelihood of HIV seropositivity (OR, 0.49; 95% CI, 0.29-0.81; Table 2 ). By contrast, sex, age, and CCR5-D32 genotype were not associated with HIV serostatus ( Table 2) . When examining the outcome of HCV serostatus, we found that co-infection with HIV and HBV and longer duration of IDU (OR, 1.24; 95% CI, 1.13-1.36) were also each associated with increased odds of HCV seropositivity, but 12 CCL3L1 copies was not associated with HCV (Table 2) or HBV serostatus (OR, 0.73; 95% CI, 0.34-1.56).
To assess the independent influence of the covariates analyzed in Table 2 on HIV and HCV seropositivity we considered the following factors. Because infections due to HCV, HBV, and HIV are all highly dependent on duration of IDU, and because these co-infections frequently occur concurrently (Table 1) , we considered the possibility that the simultaneous inclusion of all these highly correlated variables in a single multivariate logistic regression model may confound the analyses. Hence, we conducted step-wise multivariate regression analyses in which we included these covariates sequentially (Tables 3 and 4 ).
For the outcome of HIV seropositivity, we found that, in models that did not include the duration of IDU, HCV and HBV infection status was associated with a 2-fold and 4-fold higher risk of HIV seropositivity, respectively (models 1 and 4 in Table 3 ). Conversely, in the model that did not include HCV or HBV infection status, increased duration of IDU was associated with an increased risk of HIV seropositivity (model 5 in Table 3 ). By contrast, and consistent with our prediction, inclusion of IDU in the same model with HCV and HBV led to negative associations for each of these highly correlated parameters for the outcome of HIV seropositivity (models 2 and 3 in Table 3 ). However, 12 CCL3L1 copies associated with a lower risk of HIV seropositivity, independent of duration of IDU and HCV and HBV co-infection status (models 3-5 in Table 3 ). Table 4 shows that HIV seropositivity is a strong predictor of HCV seropositivity but only in those models that do not include the duration of IDU (models 1 and 4); a similar trend is observed for co-infection with HBV. However, these positive associations of HIV and HBV infection status with HCV seropositivity are not observed after inclusion of duration of IDU into the model (compare models 1 and 4 with models 2 and 3). In a model that accounts for the effects of sex and of HIV and HBV serostatus, the CCL3L1 copy number was not associated with HCV seropositivity (model 4 in Table 4 ). However, when duration of IDU was included in the model with or without HIV and HBV serostatus, a high CCL3L1 copy number was associated with an increased risk of HCV seropositivity (models 3 and 5 in Table 4 ).
Selection of high copy number in HCV-positive, HIV-negative IDUs. Table 4 shows that the associations of CCL3L1 copy number with HCV seropositivity differs before and after accounting for the duration of IDU. The latter observations raised a conundrum with respect to whether CCL3L1 copy number is associated with HCV serostatus. We surmised that a high CCL3L1 copy number was not associated with an increased risk of HCV infection, because when duration of IDU was excluded from the statistical models, a high CCL3L1 copy number did not associate with HCV serostatus (model 4 in Table 4 ). Instead, the data in Tables 3 and 4 may reflect 3 concurrent events that occur as the duration of exposure to both HIV and HCV increases. First, predictably, increasing duration of IDU increases the risk of HCV infection (models 2, 3, and 5 in Table 4 ) and HIV infection (model 5 in Table 3 ). Second, however, those who resist acquiring HIV infection are more likely to be those who also happen to have a high CCL3L1 copy number, and this might explain the increased odds ratios for a high CCL3L1 copy number when both it and duration of IDU are placed concurrently in the same model (models 3 and 5 in Table 4 ). Third, those subjects who acquire HCV infection and are also susceptible to HIV infection are less likely to possess a high CCL3L1 copy number (models 2-5 in Table  3 ). In this scenario, there should be an overrepresentation of subjects with a high CCL3L1 copy number among HCV-positive IDUs who resist acquiring HIV infection and, conversely, an underrepresentation of high CCL3L1 copy numbers in those who are both HCV positive and HIV positive.
To test this premise, we conducted 2 analyses. First, to determine whether there is an overrepresentation of high CCL3L1 copy number among HCV-positive, HIV-negative subjects and underrepresentation among HCV-positive, HIV-positive subjects, we stratified HCV-positive subjects according to their HIV infection status and conducted the logistic regression analyses. The results showed ( Table 5 ) that, consistent with our hypothesis, there was a 3.5-fold overrepresentation of a high CCL3L1 copy number among HCV-positive, HIV-negative subjects (OR, 3.57; 95% CI, 1.47-8.67), whereas there was a 65% Table 2 lower representation of a high CCL3L1 copy number among HCV-positive, HIV-positive subjects (OR, 0.35; 95% CI, 0.14-0.85). Second, to affirm further that CCL3L1 copy number does not influence risk of HCV infection, despite increased durations of IDU, we conducted the analyses shown in Table 6 . The median duration of IDU was 8 years among the study subjects. Relative to those with IDU of р8 years, those with an IDU history of 18 years had a 3-fold greater risk of HCV seropositivity (model 1 in Table 6 ). We next determined the association of CCL3L1 with HCV serostatus but, for the reasons discussed in the preceding paragraphs, we also accounted for the possible interaction between duration of IDU and CCL3L1 copy number in this model (model 2 in Table 6 ). These data indicated that duration of IDU was a strong predictor of HCV seropositivity but that CCL3L1 copy number was not (model 2 in Table 6 ).
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DISCUSSION
In this study, by examining an IDU population of Caucasian ancestry, we demonstrate that a high CCL3L1 copy number is associated with strong resistance to acquiring HIV infection. Notably, this association of CCL3L1 copy number with HIV serostatus is independent of the duration of IDU and co-infection with HCV and HBV. The specificity of this association is highlighted by the observation that, in contrast with its impact on HIV susceptibility, CCL3L1 copy number does not influence the risk of acquiring HCV infection.
The study was conducted in Estonia, a geographic region in which the introduction of HIV infection is thought to be recent, with HIV infection incidence peaking in 2001 [34, 35, 41] . Thus, infection with HCV and HBV antedated HIV infection among Estonian IDUs [35, 42] . This is reflected by the higher prevalence of HCV infection (76%), compared with that of HIV infection (56%), among our study subjects and by the fact that the duration of IDU was a stronger predictor of HCV seropositivity than it was of HIV seropositivity, with each additional year of IDU increasing the risk of HCV and HIV infection by 27%-35% and 8%, respectively. Predictably, in agreement with studies conducted in other countries [9, 41, 43] , we found that, among Estonian IDUs, HCV status was a strong predictor of HIV seropositivity and, conversely, HIV seropositivity was strongly associated with HCV serostatus. Therefore, given the very heavy exposure to multiple viral infections and the relatively recent nature of the HIV epidemic in Estonia, this IDU study group was ideal to examine the host genetic factors that confer resistance to HIV and/or HCV infection. Another strength of this study is the relative homogeneity of both the viral and host population [34] . The HIV epidemic in Estonia commenced in 2000 and was characterized by concentrated 1-source infections introduced into the IDU population during the early years of the epidemic [34] . Recent epidemiological studies have confirmed the low sequence heterogeneity of this mainly monophyletic population of recombinant circulating form HIV CRF06_cpx [44] [45] [46] . This provides an advantage, because it allows the study of the influence of host genetic factors on HIV susceptibility in the context of minimal viral genetic heterogeneity. Another strength of this study was its homogeneous study population consisted mainly of young male IDUs of Caucasian descent. In contrast to some previous studies in which distribution of CCL3L1 copy numbers in HIV-positive adults was compared with the distribution in an HIV-negative reference population, in this study, all subjects had documented exposure risk factors (eg, IDU) [24] .
Our results not only affirm the previously reported strong association of a high CCL3L1 copy number with a reduced likelihood of HIV seropositivity but also extend them significantly in 3 notable ways. First, our study provides the first evidence of this association among IDUs with heavy parenteral exposure to both HCV and HIV, a risk-group that is highly understudied with respect to the host genetic factors that influence susceptibility to viral infections. Most of the prior studies that have examined the association of CCL3L1 with HIV susceptibility have focused on either men with risk of mucosal transmission [24] or children exposed perinatally to HIV [24, [28] [29] [30] . Our results are consistent with those of Nakajima et al [32] , who found that a high CCL3L1 copy number was associated with a lower risk of acquiring HIV infection among Japanese hemophiliacs.
Second, the strength and magnitude of the association was high, and depending on the statistical model, a high CCL3L1 copy number afforded 60%-80% lower odds of HIV seropositivity. One possible mechanism for this strong association is the extensive in vitro data that shows that, among the chemokines that bind to CCR5, CCL3L1 displays the most prominent HIV suppressive activity in vitro [14] [15] [16] . However, other mechanisms are possible. Chemokines influence immune responses [18] [19] [20] [21] [22] 47] , and Dolan et al [17] showed that subjects who lacked or had a low CCL3L1 copy number had reduced cell-mediated immune responses, as estimated by delayed type hypersensitivity skin test reactions to the neoantigen KLH. Thus, it also possible that a low CCL3L1 copy may associate with increased HIV susceptibility because of both low chemokine production and impaired cell-mediated immune responses.
Third, we provide experimental evidence for the previous suggestion [24] that, among population groups that are under continuous and high exposure to HIV infection, such as among IDUs, there will be a shift in the distribution of CCL3L1 copy number over time, such that subjects who resist HIV infection will be enriched for a high CCL3L1 copy number. Given the heavy exposure to both HCV and HIV among IDUs, HCVpositive, HIV-negative subjects are traditionally categorized as highly exposed HIV-uninfected individuals. When we examined HCV-positive subjects according to their HIV infection status, we found that there was a 3-fold overrepresentation of subjects with a high CCL3L1 copy number among exposed HIV-uninfected, HCV-positive subjects and, conversely, an underrepresentation of IDUs with a high CCL3L1 copy number among HCV-positive, HIV-positive subjects. That is, the increased frequency of a higher CCL3L1 gene dose among HCV-positive, HIV-negative subjects resulted from resistance to infection with HIV among subjects who also happened to be at high risk for acquiring HCV infection. Thus, the overrepresentation of CCL3L1 among HCV-positive, HIV-negative subjects does not reflect increased susceptibility to HCV. This scenario is similar to studies by Zhang et al [39] , who suggested that the increased frequency of the protective CCR5-D32/D32 genotype among HCV-positive, HIV-negative hemophiliacs resulted from resistance to infection with HIV and not increased susceptibility to HCV. In this respect, it is noteworthy that, consistent with prior reports [12, 39] , subjects with the CCR5-D32/D32 genotype were not found among HIV-positive subjects and that, among the 4 HIV-negative CCR5-D32/D32-bearing subjects, 3 were HCV positive and HIV negative.
In conclusion, these data suggest that, among individuals at high risk for infection with both HCV and HIV, those with a low CCL3L1 copy number are preferentially infected with HIV and, conversely, those with a high CCL3L1 copy number resist infection with HIV. However, a high CCL3L1 copy number does not afford protection against acquiring infection with HCV. In turn, this differential impact of CCL3L1 copy number on the risk of HIV and HCV seropositivity shifts the distribution of CCL3L1 copy number such that HCV-positive, HIVnegative subjects have a higher CCL3L1 copy number, whereas HCV-positive, HIV-positive subjects are underrepresented among subjects with a high CCL3L1 copy number. Together, these findings suggest a possible selection by HIV for subjects with a low CCL3L1 copy number and underscore the pivotal importance of CCL3L1 and, by extension, its cognate receptor CCR5 in HIV susceptibility. In addition, our results highlight the importance of investigating the genotype-phenotype relationships for HIV serostatus in the context of microbial copathogens.
